When it comes to finding cures for cancer and providing life saving cancer treatment, Dr. Clay Siegall and his company Seattle Genetics are among some of the most prominent around. In 1998, Dr. Siegall co-founded Seattle Genetics. Throughout the years, they’ve pioneered antibody-based cancer therapies. In addition, Dr. Siegall managed to raise $675 million in capital for the company. Dr. Siegall’s determination and research led to providing life saving treatment to thousands of people.
It takes skill to raise capital in such a manner that Dr. Siegall has managed to do. Very few people have that drive. Prior to co-founding the company, Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He is also the board of directors of Alder Biopharmecuticals. To top it all off, Dr. Siegall holds more than 15 different patents and is the author of more than 70 publications. In a matter of years, Seattle genetics has managed to achieve what very few companies have, which is sustainability.
Time and time again the company has thrived under tumultuous circumstances. Since the distribution of their live saving drug ADCTERIS hit the market shelves, it has gone off to critical acclaim, achieving record sales. In addition, Seattle Genetics also has around 25 ADCs in the works. In 2016 alone, the company expects to increase revenue from $390 milion to $430 million. The aforementioned ADCs may very well become the company’s best sources of revenue. The tenacity of Seattle is evident as they continue to develop more life saving compounds.